CORZ Stock Forecast & Price Target

Core Scientific is viewed favorably because its 3Q results showed a sharp earnings inflection, with revenue of $232.9M and adjusted EBITDA of $133.6M, or $114.3M excluding digital-asset fair value effects, both well above estimates. The colocation ramp is driving the story, as billing capacity reached 485 MW, colocation revenue rose 58% sequentially to $215.4M, and margins expanded to about 60%, while management expects double-digit sequential revenue growth in 4Q26. The outlook is further strengthened by de-risked funding and execution on CoreWeave and AMD, including fully invested equity for the initial 530 MW, no expected equity issuance for that phase, and a path toward becoming a pure-play colocation provider entering 2027.

Core Scientific is viewed negatively because its growth story rests on a narrow set of counterparties, with colocation revenue concentrated in CoreWeave and AMD-related agreements, so any lease disruption or weaker customer funding could quickly pressure revenue and cash flow. The company also faces meaningful execution and financing risk: it plans to fund remaining AMD buildout with project-level debt and targeted early 2027 bonds, while regulatory hurdles, power procurement delays, and the possibility that AMD’s ~1.9 GW reservation is not fully exercised could push capacity deeper into 2027 or 2028. Heavy leverage, including $3.3B of senior secured and convertible notes plus ~186M potentially dilutive shares, further limits flexibility, while weaker AI adoption and a sector-wide valuation derate suggest the market may continue to discount the stock.